Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bornhäuser

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparationsE Schleyer, S Pursche, C H Köhne, et al.
British Journal of Haematology|July 17, 2023
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemiaJ C Peschke, R Bergmann, M Mehnert, et al.
Bone Marrow Transplantation|September 15, 2015
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)N Kröger, M Bornhäuser, M Stelljes, et al.
Leukemia|November 28, 2002
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced diseaseR Arnold, G Massenkeil, M Bornhäuser, et al.
Clinical and Experimental Immunology|January 23, 2016
Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantationC S Link, A Eugster, F Heidenreich, et al.
Leukemia|May 16, 2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLS K Metzelder, C Michel, M von Bonin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)A Thiel, J Schetelig, W Pönisch, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|June 11, 2003
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factorH G Sayer, M Kröger, J Beyer, et al.
Bone Marrow Transplantation|February 20, 2025
The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working partyL G M Daenen, L E van der Wagen, E F Bonneville, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparationsE Schleyer, S Pursche, C H Köhne, et al.
British Journal of Haematology|July 17, 2023
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemiaJ C Peschke, R Bergmann, M Mehnert, et al.
Bone Marrow Transplantation|September 15, 2015
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)N Kröger, M Bornhäuser, M Stelljes, et al.
Leukemia|November 28, 2002
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced diseaseR Arnold, G Massenkeil, M Bornhäuser, et al.
Clinical and Experimental Immunology|January 23, 2016
Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantationC S Link, A Eugster, F Heidenreich, et al.
Leukemia|May 16, 2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLS K Metzelder, C Michel, M von Bonin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)A Thiel, J Schetelig, W Pönisch, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|June 11, 2003
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factorH G Sayer, M Kröger, J Beyer, et al.
Bone Marrow Transplantation|February 20, 2025
The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working partyL G M Daenen, L E van der Wagen, E F Bonneville, et al.
Pageof 11